Infection
Update

Topics

toumei ../../image Congress Report


The 11th International Congress on Infectious Diseases
Cancun, Mexico
March 4-7, 2004


The International Society for Infectious Diseases (ISID) recently hosted the 11th International Congress on Infectious Diseases in Cancun, Mexico. More than 80 countries were represented, offering participants a global perspective of the current state of infectious diseases and a rapid update of the most pressing topics facing the infectious disease specialist.
  The need for such a global perspective has become increasingly important as we now live in a time of rapid international traffic, which has encouraged the spread of many previously geographically circumscribed infections. This is strongly illustrated by the devastating problem of SARS and the continuing spread of infections such as multi-drug resistant tuberculosis, HIV and influenza.
  ISID spearheaded the move toward international exchange, realizing that any strategy aimed at treating infectious disease will need international collaboration in order to succeed.
  The Congress included many informative symposia with world-renowned experts available to present and discuss their findings in a range of session styles. One of the overriding themes that emerged from the Congress is the need for clear-cut therapeutic strategies designed to not only effectively treat infections but also to minimize the emergence of resistance. Fluoroquinolones are seen as essential elements in many of these targeted strategies, and among this class of agents, levofloxacin remains the leader. It possesses both excellent clinical efficacy and an unsurpassed safety record.
  The following pages provide an insight into the current role of levofloxacin in the treatment of severe infections, along with a preview of its potential in important future strategies.

Highlights of Integrated Symposium:
New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation


A clinically relevant symposium aimed at providing physicians with a therapeutic plan that can be used to provide effective treatment of increasing and devastating severe infections was held on March 5. The symposium, New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation, was sponsored by Daiichi Pharmaceutical Co., Ltd. The meeting was chaired by Professor Thomas M. File, Jr., who, along with three international experts, reported on the use of levofloxacin in these situations. Overwhelmingly, these experts recommended the use of levofloxacin for a wide range of severe infections, even those caused by multiple-drug resistant pathogens. There was an increased focus on the use of higher dose levofloxacin therapy, which was shown to be extremely safe and effective.

Seated left to right are Symposium Chair, Prof. Thomas M. File, Jr., Summa Health System, Akron, Ohio, USA; Dr. David Felmingham, GR Micro, Ltd., London,UK; Prof. Thomas J. Marrie, University of Alberta, Edmonton, Alberta, Canada; and Prof. Wolfgang Graninger, University of Vienna, Vienna Austria.

  To read the reports click on the title.
   
Dr. David Felmingham
Comparative Antimicrobial Susceptibility of Respiratory Tract Pathogens
Dr. David Felmingham
GR Micro Ltd., London, UK
   
Prof. Thomas J. Marrie Experience with Levofloxacin in a Critical Pathway for the Treatment of Community-Acquired Pneumonia
Prof. Thomas J. Marrie
University of Alberta, Edmonton, Alberta, Canada
   
Prof. Wolfgang Graninger Clinical Applications of Levofloxacin in Severe Infections
Prof. Wolfgang Graninger
University of Vienna, Vienna, Austria
   
Prof. Thomas M. File, Jr., New Insights in the Treatment by Levofloxacin
Prof. Thomas M. File, Jr.
Summa Health System, Akron, Ohio, USA
   


Summarizing the Scientific Sessions -
Expanding Role for Levofloxacin in Serious Infections

PK/PD Data Reveal Advantages for High-Dose Levofloxacin Therapy
  Clinical Applications of High-Dose Levofloxacin
  High-Dose Levofloxacin More Cost-Effective in Mild to Severe CAP
  Levofloxacin Resistance Remains Extremely Rare

to_top



 

.
  ©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.
Disclaimer
Last updated May 17, 2004